Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Despite their potential usefulness as biomarkers, no study has investigated the interactions between cerebrospinal fluid (CSF) changes of neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), growth differentiation factor 15 (GDF-15), transactive response DNA binding protein (TDP-43) and interleukin-6 (IL-6) and the core AD CSF biomarkers in the same cohort of AD patients. Objectives The aim of this pilot study is to evaluate the CSF levels of these analytes in patients with AD and assess their clinical relevance in this neurological condition. Design Cross-sectional study. Methods We assessed the levels of NfL, GFAP, GDF-15, TDP-43 and IL-6 in the CSF samples of 52 early AD patients and evaluated their partial reciprocal correlations and those with Abeta42, p-Tau, t-Tau and Mini-Mental State Examination (MMSE), always adding age, sex and educational level as covariates. Results MMSE score showed a positive correlation with the Aβ 1-42 concentrations ( r = 0.485; p r = -0.418; p = 0.002). IL-6 concentrations showed a positive correlation with NfL concentrations ( r = 0.312; p = 0.026) and a negative correlation with TDP-43 concentrations ( r = -0.322; p = 0.021). TDP-43 concentrations showed a positive correlation with GFAP ( r = 0.33, p = 0.018). The mediation analysis suggests that the association between GDF-15 and MMSE is primarily mediated by Aβ 1-42. CSF GDF-15 concentrations were higher in AD patients with low Aβ 1-42 concentrations than those with high Aβ 1-42 concentrations ( p Conclusion Our findings highlight that CSF IL-6 levels correlate positively with markers of neuronal damage. CSF TDP-43 levels significantly correlated with GFAP, suggesting a potential link with reactive gliosis and astrocyte activation. In addition, while CSF GDF-15 levels negatively correlate with MMSE scores, mediation analysis revealed that this association is primarily indirect and mediated through Aβ 1-42 levels.

What this study adds

Evidence grade: Moderate

This is a cross-sectional study. In 52 patients with early Alzheimer's disease, this pilot cross-sectional study found correlations among CSF markers such as IL-6, NfL, TDP-43, GFAP and GDF-15, with GDF-15's link to MMSE mainly mediated by Aβ 1-42. It is a small pilot biomarker study and does not test any treatment, cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Plantone, D., Pardini, M., Manco, C., Righi, D., Alì, P. A., Arnaldi, D., et al. (2025). CSF IL-6, GDF-15, GFAP and NfL levels in early Alzheimer disease: a pilot study. Therapeutic advances in neurological disorders. https://doi.org/10.1177/17562864251314773

Vancouver

Plantone D, Pardini M, Manco C, Righi D, Alì PA, Arnaldi D, et al. CSF IL-6, GDF-15, GFAP and NfL levels in early Alzheimer disease: a pilot study. Therapeutic advances in neurological disorders. 2025. doi:10.1177/17562864251314773. PMID: 39974169.

BibTeX

@article{plantone2025-39974169,
  author  = {Plantone, D. and Pardini, M. and Manco, C. and Righi, D. and Alì, P. A. and Arnaldi, D. and Pelagotti, V. and Massa, F. and others},
  title   = {{CSF IL-6, GDF-15, GFAP and NfL levels in early Alzheimer disease: a pilot study}},
  journal = {Therapeutic advances in neurological disorders},
  year    = {2025},
  doi     = {10.1177/17562864251314773},
  pmid    = {39974169},
  url     = {https://doi.org/10.1177/17562864251314773}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In 52 patients with early Alzheimer's disease, this pilot cross-sectional study found correlations among CSF markers such as IL-6, NfL, TDP-43, GFAP and GDF-15, with GDF-15's link to MMSE mainly mediated by Aβ 1-42. It is a small pilot biomarker study and does not test any treatment, cure or prevention.

Study details

How this study scored 47/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 4 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 47 of 100.47 of 100 points earned53 not earned

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Therapeutic advances in neurological disorders)
Journal's citation record 1 / 4 Therapeutic Advances in Neurological Disorders: journal h-index 93 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 13 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.3 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 8.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Nicola De Stefano: h-index 98 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Genoa: institution h-index 727 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39974169)
Free to read 2 / 2 Free to read
Total 47 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →